You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.
The technology from Scanwell is also being used for its at-home SARS-CoV-2 antibody test, which is under development and awaiting Emergency Use Authorization.
The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types.
The research institute will provide blood samples to Prevencio, which will then use its artificial intelligence platform to develop a diagnostic test.
The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease.
In October the company received $15 million in funding from BARDA and venture capital firms to advance its early sepsis detection technology.
The firm looks to win new customers among US providers while also partnering with IVD companies to embed its lab data analysis tools in their instruments.
The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
The firm is developing a point-of-need blood test that it anticipates launching as an additional option in the market for active TB screening.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.